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disease have cardiovascular disease and 4.0% significant 
proteinuria using the MDRD formula; the corresponding fig-
ures using CKD-EPI are 74 and 4.6%.  Conclusions: A stan-
dardised approach to reporting case finding would allow a 
better comparison of prevalence estimates. Using a single 
eGFR tends to inflate the reported prevalence of CKD by ig-
noring creatinine fluctuation; this effect is greater than the 
difference between MDRD and CKD-EPI. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Accurate case definition is essential for the reliable 
and accurate reporting of the prevalence of a condition. 
The classic components of case definitions are time, place 
and person  [1] . Last’s  Dictionary of Epidemiology  [2]  de-
fines a case as: 
 A person in the population or study group identified as having 
the particular disease, health disorder or condition under inves-
tigation. A variety of criteria may be used to identify cases… the 
epidemiologic definition of a case is not necessarily the same as 
the ordinary clinical definition.
 Without a precise case definition, it is more difficult 
to measure trends, report unusual clusters or other oc-
currences, or measure the effectiveness of an interven-
tion. 
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 Abstract 
 Background/Aims: Cases of chronic kidney disease (CKD) 
are defined by the estimated glomerular filtration rate 
(eGFR), calculated using the Modified Diet in Renal Disease 
(MDRD) or, more recently, the CKD Epidemiology Collabora-
tion (CKD-EPI) formula. This study set out to promote a sys-
tematic approach to reporting CKD prevalence.  Design, Set-
ting, Participants and Measurements: The study explores 
the impact of the way in which eGFR is calculated on the 
prevalence of CKD. We took into account whether including 
(1) ethnicity, (2) using a single eGFR, (3) using more than
1 eGFR value or (4) using the CKD-EPI formula affected the 
estimates of prevalence.  Sample: Of 930,997 registered pa-
tients, 36% (332,891) have their eGFR defined (63% of those 
aged 50–74 years, 81%  1 75 years).  Results: The prevalence of 
stage 3–5 CKD is 5.41% (n = 50,331). (1) Not including ethnic-
ity data the prevalence would be 5.49%, (2) just using the 
latest eGFR 6.4%, (3) excluding intermediary values 5.55% 
and (4) using the CKD-EPI equation 4.8%. All changes in eGFR 
(t test) and the proportion with CKD (  2 test) were significant 
(p  ! 0.001). Using serum-creatinine-calculated eGFR instead 
of laboratory data reduced the prevalence of stage 3–5 CKD 
by around 0.01%. Sixty-six percent of people with stage 3–5 
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 Cases of chronic kidney disease (CKD) have been de-
fined using a simple formula to estimate glomerular fil-
tration rate (eGFR), the 4-variable Modified Diet in Renal 
Disease (MDRD) equation: 
 eGFR (ml/min/1.73 m 2 ) =
186.3  ! (serum creatinine/88.40 –1.154 )  ! (age –0.203 )   0.742
(if female) and   1.21 (if African-American)  [3] .
 The Kidney Disease Quality Outcomes Group re-
quires 2 eGFR measurements for a formal diagnosis of 
CKD:
 Kidney damage for  6 3 months … 
 … or GFR  ! 60 ml/min/1.73 m 2 for  6 3 months with or
without kidney damage  [4] .
 Hence the CKD case definition takes into account: 
ethnicity; a ‘constant’; 2 GFR readings, and, for stage 1 
and 2 disease, evidence of kidney damage. More recently 
a new formula – the Chronic Kidney Disease Epidemiol-
ogy Collaboration (CKD-EPI) – has been introduced. 
The CKD-EPI formula displays less bias and more preci-
sion than the MDRD formula, especially where the eGFR 
is  1 60 ml/min/1.73 m 2  [5] . 
 There are differences in the way this case definition is 
implemented. The UK’s National Guidance translates 
African American into African Caribbean  [6] , some-
times further modified into black ethnicity  [7] . The con-
stant (186.3) is not valid for all laboratory analyses  [8] , 
and so the eGFR provided by the laboratory, which in-
cludes an assay-specific correction, is more reliable than 
an eGFR calculated from a serum creatinine (SCr) value 
using the standard formula. Some studies have only used 
1 eGFR, including those used to model the UK’s national 
prevalence of CKD  [9–11] and to estimate the cost-effec-
tiveness of the implementation of national guidelines on 
CKD management  [12] . Guidance from the National In-
stitute of Health and Clinical Excellence also emphasises 
the need for chronicity in diagnosis (and implies that in-
terim values of eGFR should be taken into account), stat-
ing that for a diagnosis of CKD, the eGFR should be  ! 60 
ml/min/1.73 m 2 or there should be markers of kidney 
damage ‘on at least 2 occasions for  6 3 months’  [6] .
 A further complication is that some chemical pathol-
ogy laboratories do not report eGFR across the entire 
range  [13] but stop at eGFR  1 60 ml/min/1.73 m 2 . Finally, 
routine clinical data used for the epidemiological study 
of CKD may contain SCr readings, with or without labo-
ratory-derived eGFR recordings, and contain 1 or more 
readings of either SCr or eGFR recorded at irregular and 
inconsistent intervals.
 We carried out this study as we started a large cluster 
randomised study of quality improvement interventions 
in CKD  [14] to see if the source or type of data used to 
define CKD cases made any significant difference to the 
estimated prevalence so that we could make allowance in 
interpreting the results of our trial if the frequency of 
testing or proportion of laboratory-calculated eGFR val-
ues changed over the 2 years of the study. 
 Method 
 Overview 
 Our ‘reference’ method for defining a case of CKD stage 3–5, 
with which other diagnostic strategies were compared, was to re-
quire that the patient had had 2 measurements of eGFR, reported 
by the laboratory [and therefore using the isotope-dilution-mass-
spectrometry (IDMS)-aligned MDRD formula], both less than 60 
ml/min/1.73 m 2 and without any intervening measurements of 
GFR that were greater than 60 ml/min/1.73 m 2 .
 We developed a method of categorising the data sources used 
to define eGFR. 
 We compared the effects on mean eGFR, the proportion in 
each class of CKD, and the prevalence when we took into account:
 (1)  Variation in the way that black ethnicity is incorporated into 
estimating eGFR; 
(2)  use of a single eGFR reading; 
(3)  comparing laboratory-derived and investigator-calculated 
eGFR values; 
(4)  including interim values in CKD definition (such that the doc-
umentation of 2 eGFR readings  ^  60 ml/min/1.73 m 2  1 3 
months apart would not result in a diagnosis of stage 3–5 CKD 
if there was an intervening eGFR  1 60 ml/min/1.73 m 2 ). 
 Finally, we conducted a sensitivity analysis by comparing our 
Quality Improvement in CKD (QICKD) study case-finding meth-
od using the MDRD formula with the CKD-EPI formula, and, in 
the absence of any gold standard comparison of the accuracy of the 
GFR measure, we instead looked at the proportion of people with 
cardiovascular co-morbidities and proteinuria in the 2 groups.
 Subjects and Settings 
 We initially report the prevalence of CKD from the QICKD 
study. The study is spread across 129 practices in England – drawn 
from London and the south-east, Leicester, Birmingham and 
Cambridge. UK practices have a registration system; one person 
can only register with one practice. Individuals have a unique 
identifier (NHS number), and general practice is largely comput-
erised. A combination of technical advances, such as computer-
ised links to pathology laboratories, and pay-for-performance 
quality improvement interventions have improved record quality 
 [15] . Pseudo-anonymised routine clinical data were extracted us-
ing Morbidity Information Query and Export Syntax  [16] , the 
standard data export tool used in the UK. These data were re-
corded as part of routine care, and eGFR is reported nationally 
when renal function tests are requested. Renal function tests tend 
to be requested in UK primary care as part of chronic disease 
management and as part of the routine work-up of people who 
present unwell  [17] .
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 Reporting the Prevalence of CKD and the Source of the Data 
 We report the crude and standardised prevalence of CKD in the 
QICKD study population and the different sources of these data.
 There are 5 different possible combinations of laboratory-re-
ported and investigator-calculated eGFR.
 We have categorised them as follows:
 Category A: eGFR defined as the higher of 2 laboratory-de-
rived eGFR measurements at least 3 months apart (including not-
ing the laboratory assay method and if the laboratory is part of a 
quality assurance process);
 Category B : eGFR defined as the higher of 1 laboratory-derived 
eGFR and 1 investigator-calculated eGFR from SCr, at least 3 
months apart;
 Category C: eGFR defined as the higher of 2 investigator-cal-
culated eGFR at least 3 months apart;
 Category D: eGFR defined from a single laboratory-derived 
eGFR;
 Category E: eGFR calculated from a single SCr assessment.
 Effect on Prevalence of Including Black Ethnicity 
 We report the difference in prevalence when we include known 
black or Afro-Caribbean ethnicity. Ethnicity in primary care is 
usually self-reported but may be recorded by practice staff or cli-
nicians. Ethnicity data are coded using different hierarchies and 
with varying levels of specificity  [18] . We extract data from each 
of these code hierarchies and have developed analysis methods 
which mean we can capture the most specific code recorded for 
the patient. As no formal systems exist, we have developed our 
own mapping between the hierarchies  [19] . We explore the effect 
of applying the correction factor to people with black ethnicity 
and to those with African Caribbean ethnicity. 
 Comparing Case Finding Using a Single or Pair of eGFR 
Reading 
 We compared the effect of using the single latest eGFR for 
those people (categories A–C) for whom we have 2 readings at 
least 3 months apart.
 Correcting for the Laboratory Assay by Comparing Paired 
Laboratory- and Investigator-Calculated eGFR 
 Most creatinine assays are now standardised in the UK using 
IDMS as the gold standard, through the National External Qual-
ity Assurance Scheme  [8] . A specific IDMS-traceable version of 
the MDRD formula is then applied:
 eGFR (ml/min/1.73 m 2 ) = 175  ! (serum creatinine/88.40 –1.154 )
 ! (age –0.203 )   0.742 (if female) and   1.21 (if African-Ameri-
can).
 This uses 175 as the constant rather than the 186.3 used in the 
original MDRD formula.
 We explored the effect on prevalence and class of CKD by 
comparing paired laboratory-derived eGFR values with investi-
gator-calculated eGFR for those patients who have both recorded 
(category A). We did this by identifying the pathology laboratory 
that the individual practice used, and then contacting that labora-
tory to see if they used an IDMS-aligned assay or not. We applied 
the appropriate formula where the IDMS-traceable assay was 
used. We made the assumption that the results at a given practice 
came from their local laboratory. There is no flag within indi-
vidual results to enable any more specific analysis. 
 The Effect of Using Interim Values on the Prevalence of CKD 
 Routine data contain values at irregular intervals, and when 
identifying 2 eGFR readings at least 3 months apart there are in-
evitably varying numbers of interim values. We set up a sorting 
application to look at up to 10 interim readings, substituting the 
interim value if higher than the first or last defining value. 
 Sensitivity Analysis 
 Fluctuation in creatinine will change eGFR, and description 
of change in eGFR should provide face validity that the changes 
described in the class of eGFR are plausible. We describe the 
change in eGFR between the minimum and maximum values 
within a single year, over 2 years and over 5 years. 
 We conducted a sensitivity analysis in 2 further ways. Firstly, 
we looked at the number of people with CKD found with the 
CKD-EPI formula, using paired creatinine measurements where 
available, and taking into account laboratory assay and interim 
readings where available, to give as like-with-like comparison as 
possible with the QICKD study method. Secondly, we explored 
the proportion of cardiovascular co-morbidity and proteinuria 
found by each method of estimating eGFR; in the absence of a gold 
standard, we presumed that a better case finding formula would 
include a higher proportion of people in higher-risk groups. We 
did this by creating a variable for any existing cardiovascular dis-
ease, including hypertension and diabetes. We created 2 protein-
uria variables: ‘significant’ and ‘stick test’ proteinuria. Significant 
proteinuria was defined in the UK National Guidance; we includ-
ed all quantitative tests (24-hour tests, and total protein- and al-
bumin-to-creatinine ratios, but not dipstick tests) and also taking 
into account the different thresholds for diabetes. Significant pro-
teinuria was defined in people without diabetes as any of: an 
albumin:creatinine ratio of  1 30 mg/mmol, a total protein:cre-
ati nine ratio of  1 50 mg/mmol, a 24-hour protein excretion of
 1 0.5 g; in people with diabetes, we defined significant proteinuria 
as an albumin:creatinine ratio  1 2.5 or 3.5 mg/mmol in males and 
females, respectively. We also created a stick-test-positive protein-
uria variable; tests of 1+ or more were considered positive; trace 
was counted as a negative test.
 The Model for Categorising and Reporting Prevalence of CKD 
from Routine Data 
 We developed a reporting form based on the 5 categories de-
scribed at the start of this method to describe the source of eGFR 
measures used to define CKD prevalence. The details of the logi-
cal model are shown in the appendix and the pilot reporting form 
shown below.
 The QICKD study  [14] received ethical approval from the UK 
National Research Ethics Service in November 2008.
 Results 
 Sample 
 The sample size is approximately 1 million (n = 
930,997) patients with an age-sex distribution similar to 
the national average  [20] . There are some small differ-
ences: a small excess of men over women (50.1: 49.9%) and 
a greater proportion of working age people ( fig. 1 ). The 
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people with stage 3–5 CKD are older with many more fe-
males than males ( fig. 2 ).
 Prevalence of Stage 3–5 CKD Using the MDRD 
Formula 
 The crude prevalence of stage 3–5 CKD in our sample 
was 5.41%, with 7.34% in females and 3.48% in males. The 
standardised prevalence was the same to 2 decimal plac-
es. The proportion of males with stage 3–5 CKD in-
creased as renal function declined. The ratio of women
to men is for stage 3a, 2.2: 1; in stages 3b, 1.9: 1; in stage 4, 
1.4: 1, and roughly equal proportions in stage 5 ( table 1 ).
 36.8% of the population had an SCr or eGFR measure 
though the proportion was greater with increased age. 
80.9% of people over 75 and 63% between 50 and 74 years 
have an SCr or eGFR record. 
 Source of eGFR in the QICKD Trial Baseline Data 
 Over three quarters (76.1%) of people with stage 3–5 
CKD have at least 2 laboratory readings (QICKD catego-
ries A–C) and nearly 90% of those with stage 3b and stage 
4 disease ( table 2 ,  3 ). The lower rate of eGFR recording in 
people with normal renal function may reflect the prac-
tice of some laboratories not to report eGFR  6 60 ml/
min/1.73 m 2 .
 The Effect of Black Ethnicity on Prevalence of CKD 
 Ethnicity was reported for just under half of the popu-
lation (46.4%). A higher proportion of people with their 
creatinine measured had their ethnicity recorded (50.6%); 
the proportion was slightly higher for those with stage 
3–5 CKD, where 51.8% had their ethnicity recorded.
 People with black ethnicity recorded were approxi-
mately half as likely to have stage 3–5 CKD as those with-
out black ethnicity recorded (8.6 vs. 15.4%;   2 p  ! 0.001). 
However, they were equally likely to have stage 4 and 
more likely to have stage 5 disease. Incorporating black 
ethnicity into the equation reduced the number of people 
with stage 3–5 CKD by 1.5%; the changes that occurred 
were all into the next highest class of CKD. 
 Contrastingly, people with African Caribbean ethnici-
ty have an equal or increased prevalence of CKD. African 
Caribbean ethnicity is recorded for a subset of around half 
the black population (51.1%, n = 7,552/14,766), and unlike 
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 Fig. 1. Age and sex distribution of the 
study population (n = 930,997); lines show 
the standard English population (National 
Statistics, UK census 2001). 
 Fig. 2. Age and sex distribution of the pop-
ulation with stage 3–5 CKD (n = 50,331); 
lines show the standard English popula-
tion (National Statistics, UK census 2001). 
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other blacks in general they have an approximately equal 
prevalence of stage 3–5 CKD (14.7% of those with an eGFR 
record compared with 15.1%). Though, as with black eth-
nicity there were proportionately more cases with stage 4 
and 5 disease (8.8% of the people with stage 5 disease are 
of African Caribbean ethnicity and 3.1% stage 4 compared 
with 0.3 and 0.1% in the rest of the population). 
 Using a Single Latest eGFR 
 We compared the single latest eGFR with our more 
exhaustive process of taking into account paired and in-
terim values. Using just latest values gives a mean eGFR 
of 78.5 ml/min/1.73 m 2 , whereas using all the available 
paired eGFR produces a lower mean eGFR of 77.4 ml/
min/1.73 m 2 . As the mean is just over 1 standard devia-
tion (SD = 14 ml/min/1.73 m 2 ) the cutoff for stage 3, any 
change has a large effect on the number of individuals in 
each class of CKD. The proportion with stage 3 disease 
increases from 14.7% (n = 48,783) to 17.2% (n = 57,405); 
this change is statistically significant (  2 p  ! 0.001). Using 
the single latest eGFR value changes the prevalence of 
stage 3–5 CKD from 5.4 to 6.4%.
 Comparing Investigator- and Laboratory-Calculated 
eGFR 
 We compared the effect of using 2 laboratory-derived 
eGFR measures with using investigator-calculated eGFR. 
We compared the 53,836 people in ‘category A’ who had 
CKD class/SCr Female Male Total
No SCr measurement 279,280 (46.7) 318,826 (53.3) 598,106
Normal eGFR 34,400 (50.5) 33,751 (49.5) 68,151
Mildly impaired eGFR 117,164 (54.6) 97,245 (45.4) 214,409
Stage 3a 28,879 (68.6) 13,206 (31.4) 42,085
Stage 3b 4,349 (64.9) 2,349 (35.1) 6,698
Stage 4 693 (59.1) 479 (40.9) 1,172
Stage 5 192 (51.1) 184 (48.9) 376
Stage 3–5 CKD 34,113 (67.8) 16,218 (32.2) 50,331
All with SCr measurement 185,677 (55.8) 147,214 (44.2) 332,891
Total 464,957 (49.9) 466,040 (50.1) 930,997
R esults are patient numbers, with percentages in parentheses.
Table 1. P roportion of the population by 
gender with a creatinine measurement 
and with an eGFR by stage of CKD
Table 2.  Source of eGFR value based on the category of eGFR calculation
eGFR readings based on at least 2 measurements 
(where an intermediary value changes eGFR)
Subtotal eGFR based on a single 
measurement of eGFR
Total
A B C D E
(2 lab. eGFR) (1 lab., 1 
SCr eGFR)
(2 SCr eGFR) (1 lab. eGFR) (1 SCr eGFR)
Normal eGFR 2,528 (3.7) 4,575 (6.7) 23,970 (35.2) 31,073 (45.6) 2,293 (3.4) 34,785 (51.0) 68,151
Mildly impaired eGFR 30,651 (14.3) 21,045 (9.8) 78,052 (36.4) 129,748 (60.5) 14,919 (7.0) 69,742 (32.5) 214,409
Subtotal 33,179 (11.7) 25,620 (9.1) 102,022 (36.1) 160,821 (56.9) 17,212 (6.1) 104,527 (37.0) 282,560
Stage 3a 15,750 (37.4) 5,685 (13.5) 9,595 (22.8) 31,030 (73.7) 2,915 (6.9) 8,140 (19.3) 42,085
Stage 3b 4,010 (59.9) 509 (7.6) 1,402 (20.9) 5,921 (88.4) 374 (5.6) 403 (6.0) 6,698
Stage 4 729 (62.2) 98 (8.4) 210 (17.9) 1,037 (88.5) 85 (7.3) 50 (4.3) 1,172
Stage 5 168 (44.7) 54 (14.4) 77 (20.5) 299 (79.5) 43 (11.4) 34 (9.0) 376
Subtotal stages 3–5 20,657 (41.0) 6,346 (12.6) 11,284 (22.4) 38,287 (76.1) 3,417 (6.8) 8,627 (17.1) 50,331
Total 53,836 (16.2) 31,966 (9.6) 113,306 (34.0) 199,108 (59.8) 20,629 (6.2) 113,154 (34.0) 332,891
T he percentage in parentheses gives the proportion of each source for a given class of CKD. lab. = Laboratory.
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both laboratory-derived eGFR and 2 SCr measures. 
Again there was only a small difference in the mean 
eGFR (66.7 ml/min/1.73 m 2 for laboratory measures 
compared with 66.8 ml/min/1.73 m 2 in those derived 
from SCr). However, this small difference is again statis-
tically significant (paired-sample t test p  ! 0.001) and 
results in around 2% more people in the SCr group being 
classified as having a normal or mildly impaired eGFR 
rather than having stage 3–5 CKD ( table 4 ). Not using 
laboratory results has a much smaller effect on the popu-
lation prevalence than other factors, probably around 
0.01% reduction, if we assume that we have identified 
most people with CKD.
 The Effect of Taking into Account Interim eGFR Values 
 Taking into account any interim values for eGFR only 
increased eGFR in 3.4% of cases; however, the effect was 
greatest with declining eGFR ( table 3 ): 4.2% in stage 3a; 
6% in stage 3b; 7.3% in stage 4 (  2 p  ! 0.001); we did not 
include stage 5 because of small numbers.
 Overall, inclusion of interim values reduced the num-
ber of people with stage 3–5 CKD by 2.4%. Most of those 
Table 3.  The proportion of intermediary values that change the eGFR for paired eGFR data sources (category A–C): eGFR readings 
based on at least 2 measurements
A A int. B B int. C C int. Total for 
categories 
A–C
Total 
interim-
adj. 
eGFR
(2 lab. eGFR) (2 lab. eGFR 
adj. by 
interim)
(1 lab., 1 
SCr eGFR)
(1 lab, 1 SCr 
eGFR adj. by 
interim)
(2 SCr eGFR) (2 SCr 
eGFR adj. 
by interim)
Normal eGFR 2,441 (3.6) 87 (0.13) 4,220 (6.2) 355 (0.52) 23,221 (34.1) 749 (1.1) 31,073 (45.6) 1,191 (3.8)
Mildly impaired eGFR 29,687 (13.8) 964 (0.45) 19,970 (9.3) 1,075 (0.50) 76,198 (35.5) 1,854 (0.9) 129,748 (60.5) 3,893 (3.0)
Subtotal 32,128 (11.4) 1,051 (0.37) 24,190 (8.6) 1,430 (0.51) 99,419 (35.2) 2,603 (0.9) 160,821 (56.9) 5,084 (3.2)
Stage 3a 15,054 (35.8) 696 (1.65) 5,367 (12.8) 318 (0.76) 9,295 (22.1) 300 (0.7) 31,030 (73.7) 1,314 (4.2)
Stage 3b 3,756 (56.1) 254 (3.79) 476 (7.1) 33 (0.49) 1,331 (19.9) 71 (1.1) 5,921 (88.4) 358 (6.0)
Stage 4 682 (58.2) 47 (4.01) 91 (7.8) 7 (0.60) 188 (16.0) 22 (1.9) 1,037 (88.5) 76 (7.3)
Stage 5 160 (42.6) 8 (2.13) 53 (14.1) 1 (0.27) 75 (19.9) 2 (0.5) 299 (79.5) 11 (3.7)
Subtotal stages 3–5 19,652 (39.0) 1,005 (2.00) 5,987 (11.9) 359 (0.71) 10,889 (21.6) 395 (0.8) 38,287 (76.1) 1,759 (4.6)
Total 51,780 (15.6) 2,056 (0.62) 30,177 (9.1) 1,789 (0.54) 110,308 (33.1) 2,998 (0.9) 199,108 (59.8) 6,843 (3.4)
I nt. = Where an intermediary value changes eGFR; lab. = laboratory; adj. = adjusted. Results are patient numbers, with percentages in parentheses.
Table 4.  The effect on class of CKD of using SCr-calculated eGFR compared with using laboratory-corrected eGFR
QICKD category A
(2 laboratory-derived
eGFR)
Class of CKD from SCr
( eGFR based on 2 SCr readings)
total moves change, %
Normal eGFR 2,528 (4.7) 3,603 (6.7) 1,075 42.5
Mildly impaired eGFR 30,651 (56.9) 30,120 (55.9) –531 –1.7
Subtotal 33,179 (61.6) 33,723 (62.6) 544 1.6
Stage 3a 15,750 (29.3) 14,887 (27.7) –863 –5.5
Stage 3b 4,010 (7.4) 4,335 (8.1) 325 8.1
Stage 4 729 (1.4) 772 (1.4) 43 5.9
Stage 5 168 (0.3) 119 (0.2) –49 –29.2
Subtotal stages 3–5 20,657 (38.4) 20,113 (37.4) –544 –2.6
Total 53,836 (100.0) 53,836 (100.0) 5,269 9.8
Fi gures in parentheses indicate percentages.
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who changed class only moved up 1 class ( table 5 ). How-
ever, 2 people with stage 5 disease moved to stage 3a, 4 
from stage 3b to mildly impaired eGFR and 5 from stage 
3a to normal renal function. Although taking into ac-
count interim values has a small effect on the prevalence 
of stage 3–5 CKD, it can have a profound influence on 
individual cases.
 Sensitivity Analysis 
 The mean change in eGFR between minimum and 
readings taken in the year of the study was –0.03 ml/
min/1.73 m 2 (SD 12.7 ml/min/1.73 m 2 ; we use a minus sign 
to signify an overall rise in eGFR); the change over 2 years 
was a mean fall of 1.29 ml/min/1.73 m 2 (SD 14.5 ml/
min/1.73 m 2 ) and over 5 years a decline in 2.37 ml/min/1.73 
m 2 (SD 16.8 ml/min/1.73 m 2 ). The widening SD represents 
the bimodal distribution of the change in eGFR. Over 1 
year slightly more (of the over 33,000) paired eGFR values 
change upwards compared with down; over 2 years the 
peak for decline is larger than for increase, and over 5 years 
the changes are further exaggerated. We note how just un-
der a third (31%, n = 16,587) of people have a decline over 
5 ml/min/1.73 m 2 in 1 year and more just over a fifth (22%, 
n = 4,2960) a decline of over 10 ml/min/1.73 m 2 in 5 years.
Table 5.  Effect on class of CKD of applying different case-finding strategies
QICKD case
definition:
class of CKD
Ethnicity not included No interim eGFR included Latest eGFR only C KD-EPI prevalence
class of 
CKD
moved 
class
class of 
CKD
moved 
class
class of 
CKD
moved
class
class of 
 CKD
moved 
class
Normal eGFR 68,151 (20.5) 65,730 (19.7) –2,421 (–3.7) 65,213 (19.6) –2,938 (–4.5) 67,086 (20.2) –1,065 (–1.6) 107,823 (11.6) 39,736 (36.9)
Mildly impaired eGFR 214,409 (64.4) 216,092 (64.9) 1,683 (0.8) 216,045 (64.9) 1,636 (0.8) 20,6146 (61.9) –8,263 (–3.9) 180,113 (19.3) –33,878 (–18.8)
Subtotal 282,560 (84.9) 281,822 (84.7) –738 (–0.3) 281,258 (84.5) –1,302 (–0.5) 273,232 (82.1) –9,328 (–3.3) 287,936 (86.7) 5,858 (2.0)
Stage 3a 42,085 (12.6) 42,770 (12.8) 685 (1.6) 43,170 (13.0) 1,085 (2.5) 48,589 (14.6) 6,504 (15.5) 2,698 (3.5) –9,291 (–28.4)
Stage 3b 6,698 (2.0) 6,743 (2.0) 45 (0.7) 6,873 (2.1) 175 (2.5) 8,816 (2.6) 2,118 (31.6) 9,377 (1) 2,711 (28.9)
Stage 4 1,172 (0.4) 1,177 (0.4) 5 (0.4) 1,206 (0.4) 34 (2.8) 1,773 (0.5) 601 (51.3) 1,815 (0.2) 647 (35.6)
Stage 5 376 (0.1) 379 (0.1) 3 (0.8) 384 (0.1) 8 (2.1) 481 (0.1) 105 (27.9) 438 (0) 75 (17.1)
Subtotal stages 3–5 50,331 (15.1) 51,069 (15.3) 738 (1.4) 51,633 (15.5) 1,302 (2.5) 59,659 (17.9) 9,328 (18.5) 44,328 (13.3) –5,858 (–13.2)
Total 332,891 (100.0) 332,891 (100) 6,446 (1.9) 332,891 (100.0) 4,490 (1.9) 332,891 (100.0) 27,679 (8.3) 332,264 (100) 81,398 (24.5)
Stage 3–5 population 
prevalence
51,069 (5.49) 51,633 1,302 (5.55) 59,659 9,328 (6.41) (4.80) –5,858
Res ults are patient numbers, with percentages in parentheses.
Table 6.  Sensitivity analysis: proportion of cases with cardiovascular co-morbidity identified by different case-finding methods
QICKD case finding 
method
Not taking into 
account black ethnicity
Not taking  into account 
interim values
Using latest
creatinine/eGFR
CKD-EPI – allowance 
for SCr fluctuation as in 
QICKD
cases
with valid 
eGFR, n
CVD, valid n cases
with valid 
eGFR, n
CVD, valid n cases
with valid 
eGFR, n
CVD, valid n cases
with valid
eGFR, n
CVD, valid n cases
wit h valid 
eGFR, n
CVD, valid n
Normal eGFR 68,151 15,100 (22.16) 65,730 14,272 (21.7) 65,213 13,966 (21.42) 67,086 15,136 (22.56) 180,113 69,306 (38.48)
Mildly impaired 214,409 78,170 (36.46) 216,092 78,597 (36.4) 216,045 78,455 (36.31) 206,146 72,643 (35.24) 107,823 24,002 (22.26)
Subtotal 282,560 93,270 (33.01) 281,822 92,869 (33.0) 281,258 92,421 (32.86) 273,232 87,779 (32.13) 287,936 93,308 (32.41)
Stage 3a 42,085 25,887 (61.51) 42,770 26,249 (61.4) 43,170 26,544 (61.49) 48,589 28,987 (59.66) 32,698 22,677 (69.35)
Stage 3b 6,698 5,808 (86.71) 6,743 5,839 (86.6) 6,873 5,958 (86.69) 8,816 7,566 (85.82) 9,377 8,120 (86.59)
Stage 4 1,172 1,064 (90.78) 1,177 1,069 (90.8) 1,206 1,098 (91.04) 1,773 1,596 (90.02) 1,815 1,661 (91.52)
Stage 5 376 333 (88.56) 379 336 (88.7) 384 341 (88.80) 481 434 (90.23) 438 397 (90.64)
Subtotal 50,331 33,092 (65.75) 51,069 33,493 (65.6) 51,633 33,941 (65.74) 59,659 38,583 (64.67) 44,328 32,855 (74.12)
Total 332,891 126,362 (37.96) 332,891 126,362 (38.0) 332,891 126,362 (37.96) 332,891 126,362 (37.96) 332,264 126,163 (37.97)
Fi gures in parentheses indicate percentages; CVD = Co-morbidity with 1 or more cardiovascular diseases and/or diabetes mellitus.
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 We found that using the CKD-EPI formula the preva-
lence of stage 3–5 CKD was 4.8%. This is lower than that 
reported using the QICKD study case-finding approach 
but was a smaller difference than that between using 
paired or a single creatinine reading ( table 5 ).
 Just over two thirds (67.5%) of the people with stage 
3–5 CKD using the QICKD study case-finding method 
had co-morbid cardiovascular disease; it was only 1% less 
where 1 creatinine reading was used. However, nearly 
three quarters (74.1%) of the people with stage 3–5 disease 
identified with the CKD-EPI formula have 1 or more car-
diovascular diseases ( table 6 ). 
 The same pattern is present for proteinuria. Mainly 
due to low rates of recording in non-diabetics, the preva-
lence of significant proteinuria in stage 3–5 disease is 
3.96%. This proportion falls very slightly as elements of 
the MDRD formula are dropped. However, CKD-EPI ap-
pears to be more specific with a rate of 4.55% ( table 7 ). 
Stick tests show the same pattern; however, there are 
around one-and-a-half times as many positive results – 
10.13% of people with stage 3–5 have proteinuria when 
the CKD-EPI formula is used and 9.24% of those identi-
fied using MDRD ( table 8 ).
 Summary of Effects of Including Ethnicity, Interim, 
Just Latest and Comparing Paired eGFR Values on 
Prevalence of CKD 
 We found a prevalence of 5.41% for stage 3–5 CKD. 
However, had we used a different approach we would re-
port a different prevalence: (1) without including ethnic-
ity data prevalence would be 5.49%; (2) just using the lat-
est value it would be 6.4%; (3) not including interim eGFR 
values would give 5.55%; (4) had we used CKD-EPI and 
taken the same steps to smooth creatinine, the prevalence 
would be 4.80% ( table  5 ). Using eGFR calculated from 
SCr instead of laboratory values reduced the cases of stage 
3–5 CKD by 2.6%, potentially marginally lowering CKD 
prevalence to around 5.4% ( table 4 ). 
 Discussion 
 Principal Findings 
 Changes in estimated prevalence due to fluctuation in 
creatinine level ( fig. 3 ) are greater than those from using 
CKD-EPI instead of the MDRD formula, though CKD-
EPI identifies a much higher proportion of people classi-
fied as having stage 3–5 CKD and having cardiovascular 
co-morbidity and proteinuria than the proportion classi-
fied as CKD 3–5 using the MDRD formula.
 How investigators define cases of CKD will change 
their reported prevalence. A system of explicit reporting 
of the source of the data used to identify cases of CKD 
may enable better comparisons to be drawn between 
studies. Excluding ethnicity or interim values, or just us-
ing the latest routine clinical reading, leads to an overes-
timation of the population prevalence of stage 3–5 CKD. 
Using SCr to calculate eGFR may underestimate the 
prevalence of CKD, but only by a very small amount if the 
formula is adjusted for assay type. 
Table 7. S ensitivity analysis: proportion of cases identified with significant proteinuria identified by different case-finding methods
QICKD case-finding 
method
Not taking into account 
black ethnicity
Not taking into account 
interim values
Using latest
creatinine/eGFR
CKD-EPI – allowance 
for SCr fluctu ation as in 
QICKD
cases
with valid 
eGFR, n
significant
proteinuria,
valid n
cases
with valid 
eGFR, n
significant
proteinuria,
valid n
cases
with valid 
eGFR, n
significant
proteinuria,
valid n
cases
with valid 
eGFR, n
significant
proteinuria,
valid n
case s
with valid 
eGFR, n
significant
proteinuria,
valid n
Normal eGFR 68,151 633 (0.93) 65,730 596 (0.9) 65,213 574 (0.88) 67,086 642 (0.96) 180,113 926 (0.51)
Mildly impaired 214,409 2,359 (1.1) 216,092 2,369 (1.1) 216,045 2,365 (1.09) 206,146 2,153 (1.04) 107,823 2,027 (1.88)
Subtotal 282,560 2,992 (1.06) 281,822 2,965 (1.1) 281,258 2,939 (1.04) 273,232 2,795 (1.02) 287,936 2,953 (1.03)
Stage 3a 42,085 1,153 (2.74) 42,770 1,175 (2.7) 43,170 1,178 (2.73) 48,589 1,133 (2.33) 32,698 943 (2.88)
Stage 3b 6,698 581 (8.67) 6,743 585 (8.7) 6,873 600 (8.73) 8,816 710 (8.05) 9,377 721 (7.69)
Stage 4 1,172 193 (16.47) 1,177 192 (16.3) 1,206 199 (16.5) 1,773 264 (14.89) 1,815 271 (14.93)
Stage 5 376 68 (18.09) 379 70 (18.5) 384 71 (18.49) 481 85 (17.67) 438 84 (19.18)
Subtotal 50,331 1,995 (3.96) 51,069 2,022 (4) 51,633 2,048 (3.97) 59,659 2,192 (3.67) 44,328 2,019 (4.55)
Total 332,891 4,987 (1.5) 332,891 4,987 (1.5) 332,891 4,987 (1.5) 332,891 4,987 (1.5) 332,264 4,972 (1.5)
Figures in parentheses indicate percentages. Significant proteinuria assessed by a positive quantitative test.
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 We also note that many patients with CKD have a sub-
stantial fluctuation in their eGFR, often exceeding the 
limits in decline of 5 ml/min/1.73 m 2 over 1 year and 10 
ml/min/1.73 m 2 over 5 years set out in the National 
Guidelines  [6] . 
 Implications of the Findings 
 Both CKD-EPI and the MDRD formula power SCr 
similarly and make a similar allowance for black ethnic-
ity. Thus, whichever form of equation is used, fluctua-
tion in creatinine and adjusting for ethnicity will have a 
similar influence. Relying on a single eGFR reading 
with no allowance for fluctuation has a greater influ-
ence on prevalence than using CKD-EPI instead of 
MDRD. 
 It is possible that previous studies have overestimated 
the prevalence of CKD. The New Opportunities for Early 
Renal Intervention by Computerised Assessment (NEO-
ERICA) study used a single reading of SCr and report-
ed a prevalence of 8.2%  [10] compared with 5.4% reported 
here. If we had used a single value of SCr to calculate 
eGFR, it would have increased our prevalence to 6.4%;
if we presume the effects of ethnicity and interim values 
are additive, it would further increase the prevalence to 
6.7%. The distribution of the NEOERICA practices were 
similar but had more centres in the north of England, 
which may also have contributed to the difference  [21] . 
The Third National Health and Nutritional Examination 
Survey also appears to have used a single reading of cre-
atinine; our data would suggest that this may have over-
estimated the prevalence of CKD  [22] .
 Calculators, including our own in-house version, 
should consider limiting their description of black eth-
nicity to African American or African Caribbean  [1, 23] .
 Using this system we propose the prevalence of CKD 
would be reported providing the following data for the 
population as a whole and for people with stage 3–5 CKD: 
(1) the denominator or population size of the study; (2) 
creatinine/eGFR recording; (3) if ethnicity recording is 
available, the level of recording and how it is coded with-
in the clinical record  [18, 24] ; (4) the proportion of eGFR 
originating from each category, and (5) if interim values 
are taken into consideration.
 Using the QICKD categories when reporting studies 
based on routine data would more readily allow different 
studies to be compared and the influence of different ap-
proaches to defining a case of CKD to be more easily 
compared. 
 Further investigation is needed to explore whether the 
fluctuation in eGFR we report over 1 and 5 years repre-
sents normal variation or a missed pathological process. 
If it is the latter, revision of guidance may be needed  [6] . 
However, clinical judgement is important in both inter-
preting the significance of an eGFR reading as well as any 
decline. The existence as well as a decline of eGFR in a 
30-year-old male may be much more significant than the 
potentially explainable fluctuation in an elderly person 
with an intercurrent illness.  
Table 8.  Sensitivity analysis: proportion of cases identified with proteinuria found by dipstick (at least 1+ positive) identified by differ-
ent case-finding methods
QICKD case-finding 
method
Not taking into account 
black ethnicity
Not taking  into account 
interim values
Using latest
creatinine/eGFR
CKD-EPI – allowance 
for SCr fluctu ation as in 
QICKD
cases
with valid 
eGFR, n
significant
proteinuria,
valid n
cases
with valid 
eGFR, n
significant
proteinuria,
valid n
cases
with valid 
eGFR, n
significant
proteinuria,
valid n
cases
with valid 
eGFR, n
significant
proteinuria,
valid n
cases
wi th valid 
eGFR, n
significant
proteinuria,
valid n
Normal eGFR 68,151 10,914 (16.01) 65,730 10,989 (16.72) 65,213 10,985 (16.84) 67,086 10,666 (15.90) 180,113 5,034 (2.79)
Mildly impaired 214,409 3,161 (1.47) 216,092 3,025 (1.40) 216,045 2,978 (1.38) 206,146 3,162 (1.53) 107,823 9,163 (8.50)
Subtotal 282,560 14,075 (4.98) 281,822 14,014 (4.97) 281,258 13,963 (4.96) 273,232 13,828 (5.06) 287,936 14,197 (4.93)
Stage 3a 42,085 3,307 (7.86) 42,770 3,357 (7.85) 43,170 3,381 (7.83) 48,589 3,477 (7.16) 32,698 2,746 (8.40)
Stage 3b 6,698 949 (14.17) 6,743 957 (14.19) 6,873 977 (14.22) 8,816 1,015 (11.51) 9,377 1,219 (13.00)
Stage 4 1,172 275 (23.46) 1,177 277 (23.53) 1,206 283 (23.47) 1,773 302 (17.03) 1,815 378 (20.83)
Stage 5 376 120 (31.91) 379 121 (31.93) 384 122 (31.77) 481 104 (21.62) 438 146 (33.33)
Subtotal 50,331 4,651 (9.24) 51,069 4,712 (9.23) 51,633 4,763 (9.22) 59,659 4,898 (8.21) 44,328 4,489 (10.13)
Total 332,891 18,726 (5.6) 332,891 18,726 (5.6) 332,891 18,726 (5.6) 332,891 18,726 (5.6) 332,264 18,686 (5.6)
 Figures in parentheses indicate percentages. Significant proteinuria assessed by a positive quantitative test.  
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 Limitations of the Method 
 The opportunities and limitations of working with 
routinely collected data are well known  [25] , and it is pos-
sible that earlier work from the UK overestimated the 
prevalence and therefore the cost-consequence of this 
disease  [26] . Our first methodology paper did not take 
into account laboratory corrections or fluctuation in cre-
atinine  [9] ; subsequent work to estimate prevalence did 
but still relied on a high proportion of single readings 
 [10] . We have progressed but our data set still has limita-
tions and does not allow us to accurately model the im-
pact of these different influences on the recorded preva-
lence of CKD. However, it does form a basis for develop-
ing such a model and making comparisons between 
different studies.
 We are not directly criticising NEOERICA (S.L. and 
J.V. are co-authors); it was a study reflecting the state of 
the art at the time  [10] . We were not aware how much 
difference fluctuation in SCr might make to CKD prev-
alence, though other factors may also contribute to the 
difference in prevalence, especially the higher propor-
tion of people in QICKD who have an SCr measurement 
of 35% in this current study versus 30% in NEOERICA. 
 Although proposed as a new formula  [3] , CKD-EPI 
has not been widely introduced into clinical practice. 
CKD-EPI does reduce the estimated prevalence of CKD, 
particularly stage 3a, and it is the reduction of the size of 
this group which appears to increase the association of 
CKD with cardiovascular disease and proteinuria. There 
is controversy as to whether patients with CKD stage 3a, 
especially elderly females, have a pathological process or 
whether this is part of normal ageing  [27] .
 Comparison with the Literature 
 We could not identify the literature where similar 
comparisons have been made. More recent guidance  [6] 
has stressed the importance of SCr being measured after 
avoiding large protein meals  [28] and that the specimen 
should be analysed within 12 h  [29, 30] . However, al-
though this may reduce some of the variation between 
creatinine measures, it is unlikely to account for all the 
variation seen. Fluctuation is unlikely to be due to labora-
tory error as there is stringent quality control in the UK 
using IDMS-traceable assays  [31] .
 Call for Further Research 
 Two GFR measurements from a complete population 
would allow a perfect model to be constructed. We cur-
rently presume that we have identified most cases of 
CKD, and that we can extrapolate where there is missing 
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data. Additionally, we may be seeing regression to the 
mean, as where eGFR is ‘normal’ no further tests may be 
done, whereas if eGFR is low the test may be repeated. 
 Definitions of accelerated decline in eGFR may need 
review or to be based on more than 2 readings.
 Conclusions 
 Reports of CKD prevalence should report how they 
have allowed for fluctuation in creatinine as it may have 
a greater influence on reported prevalence than moving 
from MDRD reported cases of eGFR to using CKD-EPI. 
Studies based on single readings may significantly over-
estimate the prevalence, and study authors are recom-
mended to consider using the QICKD categories (see ap-
pendix below) to show the origins of their data. Failure to 
report how fluctuations in SCr have been taken into ac-
count may lead to greater differences in reported preva-
lence than using a different formula.
 Appendix: Model to Create Variables to 
Differentiate Categories of Source of eGFR 
Logical model and variable labels used:
Principles for defining ‘master eGFR’ to assign stages of CKD:
(1) For all source data display as separate variables for ‘code’ (in the UK the 
Read code, but it might be an ICD or SNOMED term in another health 
system), ‘date’ (the date when the data were recorded in the electronic 
patient record) and ‘value’ (its numerical value); this enables derived 
variables to be traced back to source
(2) Take latest laboratory-calculated eGFR and label this eGFR_L1 (use de-
rived eGFR if there is no laboratory eGFR)
(3) Count back 90 days and find the next laboratory-calculated eGFR = 
eGFR_L190 (or eGFR derived from SCr if there is no laboratory eGFR)
(4) Look at all eGFR recordings between these dates (only laboratory-is-
sued eGFR count if we have 2 laboratory-derived eGFR) and pick the 
highest of these; the highest value in between could be called eGFR_
L1_90_int
If this eGFR is greater than eGFR_L1 or eGFR_L1_90, then use this to 
define the stage of CKD
Laboratory-calculated eGFR interim values can trump laboratory values, 
whereas SCr interim values cannot
It does not matter how many interim values there are (eGFR_L190_int1, 
eGFR_L190_int2, eGFR_L190_int3 etc.), we use the highest
(5) eGFR results and SCr must have different dates
Detailed logical model – create the following variables:
(1) Extract code, date and value for latest laboratory-defined eGFR (latest 
laboratory-defined eGFR variable: eGFR_L1)
(2) Code data value for penultimate laboratory-defined eGFR – where it is 
more than 90 days before (penultimate laboratory-defined eGFR vari-
able: eGFR_L1_90)
(3) Code data value for highest interim laboratory-defined eGFR where 
interim if any between L1 and L1_90 eGFR >eGFR L1 or L1_90 (interim 
laboratory-defined eGFR variable: eGFR_L1_90_int)
(4) Code data value for latest creatinine (latest creatinine variable: 44J3-L1)
(5) Calculated eGFR from latest creatinine (eGFR_calc_value_1)
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(6) Code data value for penultimate SCr – where it is more than 90 days 
before (penultimate SCr44J3-L1_90)
(7) Calculated eGFR from latest penultimate creatinine at least 90 days be-
fore (eGFR_calc_value_L1_90)
(8) Code data value for highest interim SCr where interim SCr >44J3_L1 or 
>44J3_L1_90; for this highest creatinine, calculate an eGFR (variable: 
eGFR_calc_value_L1_90_int)
(9) Master eGFR – 1 eGFR code, data and value based on the following hi-
erarchy:
a Two laboratory eGFR >90 days apart; take the higher value; calculate 
from columns 1 and 2
b If not present or a higher reading between – Two lab results >90 days 
apart raised by a higher interim value Calculate from columns: (1) 
OR (2) and (3)
c If not present – take the higher value of 1 laboratory eGFR and 1 SCr-
calculated eGFR >90 days apart; calculate from columns 1 and 5
d If not present or a higher reading between – 1 laboratory eGFR and 
1 SCr-calculated eGFR >90 days apart raised by a higher interim val-
ue; calculate from columns 1 or 5 and 8
e If not present – take the higher value of 2 SCr-calculated eGFR >90 
days apart; calculate from columns 5 and 7
f If not present – take the higher value of 2 SCr-calculated eGFR >90 
days apart raised by a higher interim value; calculate from columns 
5 or 7 and 8
g If not present – 1 laboratory eGFR; calculate from column 1
h If not present – 1 SCr-calculated eGFR; calculate from column 5
N.B. Only 1 value appears depending on its origin; the date is the date 
of the eGFR contributing to the calculation
(10) Basis of master eGFR:
a Category Aint. – 2 laboratory eGFR >90 days apart
b Category A – 2 laboratory results >90 days apart raised by a higher 
interim value
c Category Bint. – 1 laboratory eGFR and 1 SCr-calculated eGFR >90 
days apart
d Category B – 1 laboratory eGFR and 1 SCr-calculated eGFR >90 days 
apart raised by a higher interim value
e Category Cint. – 2 SCr-calculated eGFR >90 days apart
f Category C – 2 SCr-calculated eGFR >90 days apart raised by a high-
er interim value
g Category D – 1 laboratory eGFR
h Category E – 1 SCr-calculated eGFR
i Only 1 category number appears in this column
(11) Date of most recent (latest) eGFR or SCr used; date of column 1 or col-
umn 5
(12) Date of penultimate (L1_90) eGFR or SCr used or interim higher 
‘trumping’ value; date of column 2 or 3 or 7 or 8 …
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